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A semi-random mutagenesis approach was followed to
increase the performance of penicillin acylase PAS2 in the
kinetically controlled synthesis of ampicillin from 6-amino-
penicillanic acid (6-APA) and activated D-phenylglycine
derivatives. We directed changes in amino acid residues to
positions close to the active site that are expected to affect the
catalytic performance of penicillin acylase: aR160, aF161
and bF24. From the resulting triple mutant gene bank, six
improved PAS2 mutants were recovered by screening only
700 active mutants with an HPLC-based screening method.
A detailed kinetic analysis of the three most promising
mutants, T23, TM33 andTM38, is presented. Thesemutants
allowed the accumulation of ampicillin at 4–5 times higher
concentrations than the wild-type enzyme, using D-phenyl-
glycine methyl ester as the acyl donor. At the same time, the
loss of activated acyl donor due to the competitive hydrolytic
side reactions could be reduced to <20% with the mutant
enzymes compared to >80% when using wild-type PAS2.
Although catalytic activity dropped by a factor of 5–10,
the enhanced synthetic performance of the recovered peni-
cillin acylase variants makes them interesting biocatalysts
for the production of b-lactam antibiotics.
Keywords: b-lactam antibiotics/penicillin acylase/
semi-random mutagenesis/synthesis
Introduction
For several decades, penicillin acylase (penicillin amidase, PA,
EC 3.5.1.11) has been used for the hydrolytic release of
6-aminopenicillanicacid (6-APA)fromfermentativelyobtained
natural penicillins, which is a central step in the production of
semi-synthetic b-lactam antibiotics. Recently, also biocatalytic
processes using this enzyme for the kinetically controlled con-
densation of activated acyl moieties with 6-APA or other
b-lactam nuclei have been developed (Bruggink et al., 1998).
Althoughcompetitivewith traditionalchemical synthesis routes,
these enzymatic procedures suffer from the fact that the desired
synthesis of b-lactam antibiotics is accompanied by two side
reactions, leading to the loss of activated acyl donor and limiting
the product yield: (1) hydrolysis of the activated acyl donor and
(2) hydrolysis of the formed antibiotic. Efforts to overcome this
problemhavemostly focusedon a change in reaction conditions,
such as pH optimization (Youshko et al., 2002b), the use of
supersaturated substrate solutions (Youshko et al., 2004) or
immobilizedenzymepreparations (Alvaroetal., 1990)andmed-
ium engineering (Fernandez-Lafuente et al., 1996). However, it
was shown that the intrinsic kinetic properties of the biocatalyst
employed also have a major impact on the efficiency of the
synthetic reaction (Hernandez-Justiz et al., 1999; Youshko
et al., 2002a; Alkema et al., 2003).
During PA-catalyzed antibiotic synthesis, the formation of
the synthetic product Ps, i.e. the antibiotic, and also the for-
mation of the hydrolytic byproduct Ph proceed via the forma-
tion of a covalent acyl-enzyme intermediate EAc, which is the
rate-limiting step in the catalytic process (Figure 1). EAc can
then be attacked by one of two possible nucleophiles: either the
b-lactam nucleus N, leading to the desired product Ps, or by a
water molecule, which results in the formation of Ph. The ratio
between the initial production rates of synthetic product (vPs)
and hydrolytic product (vPh) and the maximum level of product
accumulation that is obtained (Psmax) depend on the initial
concentrations of b-lactam nucleophile N and acyl donor
AD and the kinetic parameters of the enzyme. In fact, antibiotic
formation in PA-catalyzed reactions is sufficiently described
by only three complex kinetic parameters, a, b0 and g , accord-
ing to Equation 1 (Youshko et al., 2002a):
d Ps½ 
d Ph½  =
b0 N½  AD½ a Ps½  1 + b0g N½ ð Þ
1 + b0g N½ ð Þ AD½  + a Ps½ ð Þ
ð1Þ
with [AD]0 = [AD] + [Ps] + [Ph] and [N]0 = [N] + [Ps].
Experimentally, parameters b0 and g can be directly deter-
mined, since they relate the initial rates of product and byprod-
uct formation to the concentration of nucleophilic b-lactam











+ N½  ð2Þ
where 1/g is the maximum that is reached for [N] ! ¥ and b0
is the initial slope of a (vPs/vPh)ini vs. [N] plot. The third
Fig. 1. Kinetic scheme of the synthesis and hydrolysis reactions catalyzed by
penicillin acylase via the formation of a covalent acyl-enzyme intermediate
EAc. Designations: E, free enzyme; AD, activated acyl donor; E.AD, non-
covalent enzyme–acyl donor complex; P1, first reaction product that is
released upon acylation of the enzyme; Ph, product of hydrolysis reactions;
N, b-lactam nucleophile; EAc.N, covalent acyl-enzyme intermediate with non-
covalently bound nucleophile; Ps, product of the synthesis reaction, i.e. the
antibiotic; E.Ps, enzyme–antibiotic complex. Rate constants kac, kh1, kh2, ks
and k–s refer to different reaction steps as indicated in the scheme. KAD, KPs
andKN are the binding constants of AD and Ps to the free enzyme and of N to the
acyl-enzyme intermediate, respectively.
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parameter, a, introduces the fact that the synthesized antibiotic











The parameter a actually reflects the relative specificity of PA
for the antibiotic with respect to the activated acyl donor and
should be as small as possible to allow high product accumula-
tion in a synthesis reaction. The parameters b0 and 1/g , in
contrast, preferably should be high to prevent the formation
of large amounts of hydrolytic byproduct. The use of a PA with
favorable kinetic parameters for the synthesis of a specific
antibiotic thus takes a key position in the design of an efficient
production process.
Biocatalysts with desired properties can be obtained either
from nature, applying search strategies that range from tradi-
tional screening of culture collections to screening of meta-
genomic gene banks (Handelsman et al., 1998; Lorenz et al.,
2002) or by improving already available enzymes (Kazlauskas,
2000; Zhao et al., 2002). Examples for the first approach are the
PAs of Kluyvera citrophila, Bacillus megaterium, Proteus
rettgeri and Alcaligenes faecalis, which were all detected
for the first time by assaying pure bacterial cultures (Huber
et al., 1972; Barbero et al., 1986). Unfortunately, none of these
enzymes seems to be better suited for synthetic purposes than
the already known PA of Escherichia coli (Hernandez-Justiz
et al., 1999). In contrast, an enzyme with better kinetic proper-
ties for 6-APA-derived antibiotic production, PAS2, was isol-
ated from a soil metagenomic gene library (Gabor et al.,
2004a). PAS2 allows significantly improved antibiotic yields
and, concomitantly, lower amounts of hydrolytic byproduct
than the industrially employed E.coli PA with which it has
51.4% of its amino acid residues in common (Gabor et al.,
2004b). Like the E.coli enzyme, PAS2 is a periplasmatic
enzyme that consists of an a-subunit (25.5 kDa) and a
b-subunit (61.9 kDa).
In this study, we explored the possibility of further increas-
ing the synthetic performance of PAS2 for ampicillin produc-
tion, using a semi-random mutagenesis procedure. By
simultaneous randomization of three amino acid residues
close to the active site, a gene library comprising 6000 original
mutants was created. Since the three selected residues are
known to affect greatly the kinetic properties of E.coli PA
(Alkema et al., 2000, 2002a), we anticipated that the mutants
would show significant variations in catalytic behavior. Indeed,
six clearly improved enzymes were found on screening only
700 active mutants. A detailed kinetic analysis of the three
most promising PAS2 derivatives is presented.
Materials and methods
Chemicals
Ampicillin and cephalexin were purchased from Sigma.
D-Phenylglycine (PG) was obtained from Acros. 6-Aminopeni-
cillanic acid (6-APA), 7-aminodesacetoxycephalosporanic
acid (7-ADCA), D-phenylglycine methyl ester (PGM) and
D-phenylglycinamide (PGA) were provided by DSM Life
Sciences (Delft, The Netherlands). The colorimetric substrate
2-nitro-5-[(phenylacetyl)amino]benzoic acid (NIPAB) was
synthesized according to the following procedure: 5.08 g of
5-amino-2-nitrobenzoic acid were dissolved in 200 ml of dry
acetone, to which 4 ml of phenylacetyl chloride were added
slowly. A solid precipitate formed after 30 min and the mixture
was stirred at room temperature overnight. After filtration, the
yellow acetone solution was concentrated to 50 ml and added
dropwise to 250 ml of vigorously stirred water. The product
precipitated as a slightly yellow solid, which was recrystallized
from water to give a white solid (3.80 g yield, i.e. 91% based on
the fact that only 50% of the amine reacts and the other half acts
as a base to neutralize the liberated HCl). 1H NMR (400 MHz,
DMSO-d6), d (ppm): 3.50 (s, 1H, COOH); 3.65 (s, 2H, CH2);
7.19–7.27 (m, 5H, Ph); 7.79 (d, 1H, Ph); 7.95 (m, 2H, Ph);
10.77 (s, 1H, NH). Phenylacetyl-L-leucine (PAL) was obtained
through standard organic chemical peptide coupling chemistry:
6.55 g of L-leucine were dissolved in 50 ml of 2 M NaOH. The
solution was cooled to <10C, then 8.5 g of phenylacetyl
chloride were added dropwise, keeping the temperature
<10C and the pH >10. After complete addition, the mixture
was allowed to warm up to room temperature and was stirred
for a further 1 h. The water was acidified to pH 4 with con-
centrated phosphoric acid to precipitate the product. Filtration
and washing with ample amounts of water to remove traces of
phenylacetic acid gave the product, which was recrystallized
from hot water–ethanol. Drying under vacuum yielded 7.1 g of
PAL (57%), m.p. 131–132C (uncorrected). HPLC analysis
showed that there was <0.7% phenylacetic acid in the sample.
1H NMR (300 MHz, DMSO-d6), d (ppm): 0.90 (dd, 6H, CH3);
1.40–1.65 (m, 3H, CHCH2); 3.42 (s, 2H, CH2); 4.19 (m, 1H,
Ca); 7.18–7.35 (m, 5H, Ph); 8.35 (d, 1H, NH). 13C NMR
(300 MHz, DMSO-d6), d (ppm): 21.3 (CH3); 22.9 (CH3);
24.4 (CH); 42.0 (CH2); 50.3 (Ca); 126.3 (CH); 128.2 (CH);
129.0 (CH); 136.4 (Cq); 170.2 (CO); 174.2 (CO).
Plasmids and strains
For all plasmid constructs described in this study, E.coli TOP
10 [D(Ara–Leu )7697, Invitrogen] was used as the host organ-
ism. pBADPAS2 is a 6.7 kb plasmid carrying the wild-type
pas2 gene under the control of the pBAD promoter (Gabor
et al., 2004b). pPAS2CAT is a similar construct, just conferring
chloramphenicol instead of ampicillin resistance to prevent
interference of b-lactamase activity with b-lactam antibiotic
synthesis experiments in whole cells. To obtain this construct,
pBADPAS2 was cut with BspHI (New England Biolabs) to
remove the b-lactamase gene. The remaining 5.7 kb fragment
was isolated from gel with a QIAEX II gel extraction kit
(Qiagen), blunted with Klenow polymerase (Invitrogen) and
ligated to an also gel-purified blunt 1.2 kb fragment with T4
ligase (Invitrogen). The 1.2 kb fragment carried a chloramphe-
nicol acetyltransferase gene (cat) and originated from the plas-
mid pEC (provided by DSM, Delft, The Netherlands) (Alkema
et al., 2000), from which it was removed by BspHI/EcoRI
restriction (New England Biolabs). All DNA manipulations
were carried out according to the instructions of the manufac-
turers of the materials used. The construct was transferred to
E.coli by electroporation and confirmed by restriction analysis.
All media used to grow clones carrying the wild-type
pPAS2CAT plasmid or mutant derivatives were supplied
with 68 mg/l of chloramphenicol.
Triple site-saturating mutagenesis
Two degenerate primers were designed, one for the random
mutagenesis of amino acid residues aR160 and aF161
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(50 gtg ggc act atg gcc aac nng/c nng/c tcg gac gcc aat agc gaa
atc g 30) and one for position bF24 (50 ggc ggg gtt cca cca gcc c/
gnn ctg cgg gcc gtt taa cag 30). For the easy identification of
real mutants, primer aR160X/aF161X was set up to remove a
unique NcoI restriction site and primer bF24X to introduce an
additional MseI site, both leading to characteristic differences
in the restriction patterns of wild-type and mutant plasmids
(restriction sites underlined, mutations in bold). To reduce
codon bias, the third position of each random codon was
fixed to be a guanine or a cytosine. An outline of the used
mutagenesis procedure is shown in Figure 2. In the first step, a
500 bp fragment containing all three randomized codons was
PCR amplified with the two degenerate primers described
above. The reaction was carried out with Pfu Turbo polymerase
(Stratagene) under standard conditions, using 50 ng of
pPAS2CAT as the template and 125 ng of each of the primers.
The amplified fragment (megaprimer) was purified on gel with
a QIAEX II gel extraction kit (Qiagen) and used as a forward
and reverse primer set in a normal QuikChange site-directed
mutagenesis procedure (Stratagene) according to the instruc-
tions of the manufacturer. After ethanol precipitation, the reac-
tion mixture was resuspended in water and mutant plasmids
were transferred to E.coli TOP10 by electroporation. Trans-
formants were plated on LB agar (Sambrook et al., 1989).
Mutant strains obtained by this procedure usually carry two
plasmid populations with different mutations, one originating
from each of the different strands of the original (chimeric)
mutant plasmid. To solve this problem, all colonies were
washed from the agar plates and used for plasmid preparation
with a High Pure Plasmid Isolation Kit (Roche). The plasmid
mix was then retransferred to E.coli to produce transformants,
each carrying only one type of plasmid. The resulting amplified
gene bank was then subjected to growth selection and screen-
ing. By enzymatic digestion of 20 single clones with NcoI and
MseI, the library was shown to contain >95% of triple mutants.
Interesting mutants were sequenced with at least two times
coverage of each base by BaseClear Holding (Leiden, The
Netherlands). All sequences obtained were different.
Selection of active mutants and screening for improved
synthesis
Activemutants were selected by their ability to grow on phenyl-
acetyl-L-leucine (PAL) as the sole source of leucine (Forney
and Wong, 1989) in a minimal medium supplied with 0.2%
(w/v) glucose and 15 g/l agarose as described previously
(Gabor et al., 2004a). PAL was added at a concentration of
10 mg/l and 0.2% (w/v) arabinose wase included in the medium
to induce protein expression from PBAD. After 5 days of growth
at 30C, single colonies were transferred from the agar plates to
96-well microtiter plates (MTPs) filled with 200 ml of liquid LB
medium per well. After overnight incubation at 30C and
200 r.p.m. orbital shaking, 50 ml of 50% glycerol were added
per well and plates were stored as frozen stocks at 80C.
For the first round of screening by high-performance liquid
chromatography (HPLC), plates were defrosted and 20 ml ali-
quots of the stock cell suspensions were transferred to fresh
MTPs and used to inoculate 180 ml of LB medium. MTPs were
incubated at 17C with orbital shaking at 200 r.p.m. for 48 h,
then 50 ml of 10% arabinose solution were added. An arabinose
concentration of 2% in the culture medium resulted in the
highest level of protein expression as established in prelimin-
ary experiments with the wild-type strain. After incubation for
a further 24 h at 17C, cells were collected by centrifugation for
5 min at 2500 r.p.m. in an MSE Mistral 2000 MTP centrifuge.
They were resuspended in 200 ml of substrate solution per well
(15 mM PGA and 10 mM 6-APA in 50 mM potassium phos-
phate buffer, pH 7.0) and incubated at 30C. After 24 h, 10 ml
of the reaction mixtures were transferred to fresh MTPs and
quenched by the addition of 90 ml of HPLC eluent [340 mg/l
sodium dodecyl sulfate and 680 mg/l KH2PO43H2O in 30:70
(v/v) acetonitrile–water of pH 3.0 (adjusted with dilute phos-
phoric acid)]. Liquid handling was performed with a Plato 3001
automated pipetting station (Rosys, Switzerland) that also
served as a 96-well MTP format autosampler for HPLC injec-
tion. HPLC analyses were carried out using a 3 cm Alltech
Alltime C18 3u column in connection with Jasco PU-980
pumps and a Jasco MD-910 detector set at 214 nm. Compounds
Fig. 2. Mutagenesis procedure used in this study. In the first step, a PCRproduct
is prepared, using two degenerate primers that carry the desired randomized
codons and the wild-type plasmid as the template. This product is then used as a
megaprimer (three randomized positions) in a standard QuikChange site-
directed mutagenesis procedure (Stratagene) to yield the desired triple mutants.
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were isocratically eluted at a flow rate of 5 ml/min with HPLC
eluent, which allowed the analysis of one sample in 3 min. The
ratio of the areas of the product peaks, i.e. ampicillin and PG, in
each chromatogram was determined and compared with that of
the E.coli (pPAS2CAT) control. Mutant strains exhibiting at
least a 2-fold increased ampicillin/PG peak ratio or showing
exceptionally high conversion rates were analyzed in more
detail for their performance in the synthesis of ampicillin.
In this second round of HPLC screening, complete progress
curves for the synthesis of ampicillin from 15 mM PGA and
25 mM 6-APA in 50 mM potassium phosphate buffer (pH 7.0)
were recorded at 30C, using periplasmatic extracts and
enzyme concentrations of 5–10 mM. Extracts were prepared
and analyzed for their content of active penicillin acylase as
described in the next paragraph. A similar HPLC setup as for
the robotic screening served for this analysis, but based on a
10 cm Chrompack C18 column. Here, compounds were eluted
isocratically at a flow rate of 1 ml/min. Peak areas were related
to the concentration of the respective compounds using calib-
ration curves that were established with solutions of the pure
compounds.
Preparation of periplasmatic extracts and enzyme purification
Periplasmatic extracts were prepared at different scales. For the
verification of whole cell screening results in the second round
of HPLC screening, 5 ml cultures were used as a starting
material, while 1 l cultures were used for protein purification.
In both cases, clones containing the wild-type or mutant PAS2
gene were grown in LB at 17C with rotary shaking at
200 r.p.m. After 2 days of growth, the medium was supplied
with 0.8% arabinose for the induction of protein expression.
After a further 24 h of incubation, cells were harvested by
centrifugation at 5000 g for 10 min (4C). To prepare a peri-
plasmatic extract, cells were resuspended in one-tenth of the
original culture volume of ice-cold osmotic shock buffer
(20% sucrose, 100 mM Tris–HCl, 10 mM EDTA; pH 8.0)
and centrifuged as described above. Cell walls were disrupted
by resuspending the cell pellet in one-fiftieth of the original
culture volume of ice-cold 1 mM EDTA and cell debris was
removed by another centrifugation step.
Wild-type PAS2 and mutant enzymes were purified as
described previously (Gabor et al., 2004b). The amount of
active enzyme in penicillin acylase preparations was deter-
mined by titration with the irreversible inhibitor phenylmethyl-
sulfonyl fluoride (PMSF) according to Alkema et al. (1999).
Enzyme preparations were incubated with different concentra-
tions of PMSF in 50 mM potassium phosphate buffer (pH 7.0)
at room temperature for 15 min. Residual activity was meas-
ured with NIPAB or ampicillin as a substrate. The release of
5-amino-2-nitrobenzoic acid from NIPAB was followed spec-
trophotometrically at 405 nm (De405 nm = 9.09 mM1 cm1)
with a Perkin-Elmer Bio40 UV/VIS spectrometer, and hydro-
lysis of ampicillin was monitored by withdrawing samples
from the reaction mixtures at different time points in the initial
phase of conversion and analyzing them by HPLC (10 cm
Chrompack C18 column).
Determination of kinetic parameters
All enzymatic conversions were carried out in 50 mM potas-
sium phosphate buffer (pH 7.0) at 30C. Steady-state kinetic
parameters of the mutant enzymes for the hydrolysis of
PGA, PGM, ampicillin and cephalexin were determined by
monitoring the initial rates of substrate conversion at various
substrate concentrations by HPLC (10 cm Chrompack C18
column). Product concentrations were determined at several
times in order to obtain at least three data points in the initial
phase of conversion. Steady-state parameters of PAS2 were
determined as described previously (Gabor et al., 2004b).
Kinetically controlled enzymatic synthesis of ampicillin and
cephalexin was carried out by mixing enzyme with solutions of
activated acyl donor (PGA or PGM) and 6-APA or 7-ADCA,
respectively. The initial concentration of acyl donorwas 15mM
in all experiments, and the concentration of b-lactam acyl
acceptor varied between 0.5 and 200 mM. All reactants
were monitored in time by HPLC analysis (10 cm Chrompack
C18 column) and initial rates of formation of the antibiotic (vPs)
and the hydrolyzed acyl donor (vPh) were determined.
Results and discussion
Structure-inspired semi-random mutagenesis
Penicillin acylase PAS2 (accession No. AY573298) and E.coli
PA (accession No. AAA24324) share 51.4% of their amino
acid residues. This degree of sequence identity was sufficiently
high (>25%) to obtain a homology model of PAS2 based on
the known 3-D structure of the E.coli enzyme (Duggleby et al.,
1995). The model provided by the Swiss-Model service
(http://www.expasy.org/swissmod/SWISS-MODEL.html) did
not reveal significant changes in the geometry of the active
site and the spatial orientation of several amino acid residues
that were shown to affect significantly the catalytic behavior of
E.coli PA (Alkema et al., 2002a,b) perfectly matched between
the two proteins. This agreement and the conservation in a
number of different other PAs, such as of Proteus rettgeri
(accession No. A56681), Alcaligenes faecalis (accession No.
AAD11517) and Kluyvera citrophila (accession No. A26528),
prompted us to chose the three residues aR160, aF161 and
bF24 of PAS2 (corresponding to positions a145, a146 and b24
in E.coli PA) as targets for mutagenesis. Alkema et al. (2000)
showed that residues aR145 and aF146 have an important
impact on the affinity of the E.coli enzyme for phenylacety-
lated substrates and the positioning of substrates towards the
catalytic serine in the active site. Via an induced fit mechanism,
they participate in the formation of the b-lactam binding site.
When 6-APA or derived antibiotics are bound, both residues
interact with the b-lactam moiety: aR145 with the negatively
charged carboxylate group via two bridging water molecules
and aF146 by van der Waals interactions with the 2b-methyl
group of the thiazolidine ring (Done et al., 1998; Brannigan
et al., 2000). The phenyl ring of the side chain of aF146 also
participates in the formation of the acyl donor binding pocket
by interacting with the phenyl ring of the acyl compound. On
the other side of the binding pocket, another phenylalanine is
located, bF24, which also shows hydrophobic interaction with
the acyl donor (Alkema et al., 2002a).
Although the importance of the three residues in E.coli
PA—and most likely also in PAS2—is obvious, it is difficult
to predict what effect a specific mutation will have on the
catalytic performance of the enzyme in a kinetically controlled
synthesis reaction, because both the activated acyl donor and
the antibiotic can serve for the formation of the covalent acyl-
enzyme intermediate (EAc). Therefore, optimization of e.g.
the enzyme acylation reaction in order to increase the reactivity
E.M.Gabor and D.B.Janssen
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with the acyl donor usually also results in improved hydrolysis
of the antibiotic formed. Also, engineering the enzyme with
respect to improved deacylation by the b-lactam nucleophile is
not straightforward, since increased reactivity of the b-lactam
nucleophile is often accompanied by an increased specificity
also for the b-lactam antibiotic. In the end, only subtle changes
in the geometry of the acyl-enzyme or the orientation and
activation of the deacylating nucleophiles cause altered rates
of product and byproduct formation and influence Psmax. These
changes are mostly difficult to rationalize, which is particularly
true for PAS2, for which an experimental 3-D structure is not
yet available. Therefore, we chose to randomize the respective
amino acid residues rather than to follow a completely rational
approach. By simultaneously changing residues at three differ-
ent sites, we were able to create a gene bank of high sequence
diversity, while focusing on mutants that are likely to show
significantly altered catalytic performance.
The procedure used to create the triple mutant bank of PAS2
is illustrated in Figure 2. Since two of the target positions for
randomization concern adjacent amino acid residues, we only
needed to design two degenerate primers: one for aR160 and
aF161 and another for residue bF24. With these two primers, a
(double-stranded) megaprimer was prepared by simple PCR
amplification that could subsequently be used in a standard
QuikChange mutagenesis procedure. In this way, 6000 original
clones were created that were stored as an amplified gene
library and screened for improved ampicillin synthesis.
Screening for higher ampicillin yields
The development of a direct screening method for increased
antibiotic yields, e.g. by HPLC analysis, is difficult owing
to the temporary nature of product accumulation. After
reaching a maximum (Psmax), the product concentration
decreases owing to the enzymatically catalyzed hydrolysis
of the antibiotic. Earlier experiments showed that an increase
in (vPs/vPh)ini at fixed reaction conditions is often coupled to
an increase in Psmax and can therefore be used as an alter-
native screening criterion (Alkema et al., 2002a). This is in
agreement with Equation 1, which shows that an increase in
b0 and/or 1/g (reflected by an increased rate ratio of synthetic
and hydrolytic product formation) results in a higher Psmax if
a remains unchanged or is even decreased. A problematic
feature of this screening approach is the fact that
improved mutants with respect to Psmax might be missed if
they possess a superior a parameter, but have a similar (vPs/
vPh)ini as the wild-type enzyme. In the same way, mutants
might seem improved upon screening, while actually not
yielding more product if they have an unfavorably high a,
which causes preference for the product over the activated
acyl donor during enzyme acylation. Despite these limita-
tions, we chose to use a screening procedure based on the
described principle because of its relatively high throughput
capacity and refine the search by a second, more detailed
round of analysis.
In the first round of HPLC screening, cell suspensions of
mutant clones were analyzed in MTPs for the produced
amount of Ps (ampicillin) and Ph (D-phenylglycine, PG)
from D-phenylglycine amide (PGA) and 6-APA at a certain
time. PGA was used as the acyl donor owing to its high che-
mical stability and, consequently, low background hydrolysis
under the applied reaction conditions. The peak ratio of
ampicillin/PG formed after 24 h was compared with that of
a wild-type PAS2 culture. Since we could not assume all reac-
tion mixtures to be in the initial phase of conversion and the
peak ratio changes in the course of reaction, several wild-type
cultures with different induction levels were prepared in order
to obtain a set of chromatograms with varying degrees of
conversion. Each mutant chromatogram was then compared
with the wild-type profile that showed the most similar con-
version level. With this method, one 96-well MTP could be
analyzed in about 5 h, leading to a maximum throughput of four
plates per day. In order to decrease the number of clones that
needs to be screened, clones expressing an active PAS2 variant
were preselected on agar plates containing D-phenylacetyl-L-
leucine (PAL) as the only source of leucine. Since only 20% of
all mutants were found to be active, the screening effort for
synthetic activity was reduced by a factor of 5 by only analyz-
ing mutants that could grow on PAL medium. A total of 700 of
these clones were subjected to a first round of HPLC screening
(Figure 3).
In preliminary experiments, we had compared the recovery
of active clones by this growth selection method with
the detection of activity in MTPs due to the hydrolysis of
2-nitro-5-[(phenylacetyl)amino] benzoic acid (NIPAB), which
is a well-known colorimetric substrate for penicillin acylases
(Kutzbach and Rauenbusch, 1974). While all clones able to
hydrolyze NIPAB were also found to grow on PAL, about 15%
of the clones utilizing PAL could not hydrolyze NIPAB, which
made us decide to use PAL for the recovery of active clones.
Interestingly, the six truly improved mutants isolated in
this study (see below) could not hydrolyze NIPAB or only
at extremely low rates, which would have compromised
their isolation if a prescreening on NIPAB had been included.
Besides selection on PAL plates, we also isolated trans-
formants that could grow on medium supplied with amides
such as D-phenylglycine amide, a-methylphenylglycine or D-
mandelamide (racemic mixture) as the only source of nitrogen.
However, none of the 500 mutants selected on these media
showed promising ampicillin/PG peak ratios or high activity
when tested for ampicillin synthesis. FromthePALpreselection,
incontrast,50clonesexhibitedenhancedsyntheticbehavior.The
recovery of improved mutants from PAL plates but not from
nitrogen-limited media can be attributed to the fact that only
traces of leucine need to be released by hydrolysis to sustain
growth, while local concentrations of nitrogen are required to
Fig. 3. Screening for improved PAS2 mutants by HPLC with whole cells.
Clones represented by black dots were inspected in more detail in a second
round of HPLC screening with periplasmatic extracts. Truly improved mutants
that were subjected to further analysis are indicated by surrounding circles.
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be in themMrange for the formationof reasonablysizedcolonies.
Mutants that show improved synthetic performance but reduced
hydrolytic activity may consequently not be able to grow on
nitrogen-limited media.
The 50 improved mutants from the PAL preselection were
tested in more detail in a second round of HPLC analysis. Here,
complete progress curves for the kinetically controlled synth-
esis of ampicillin from PGA and 6-APA were recorded to
reveal whether the respective mutant indeed allowed higher
maximum product accumulation than the wild-type. Six of the
mutants showed significantly improved synthetic performance
and were subsequently also tested with another common
b-lactam nucleophile, 7-ADCA, in the synthesis of cephalexin.
Dependence on the type of acyl donor was revealed by using
either PGA or the methyl ester derivative of D-phenylglycine,
PGM, as the acyl moiety. Improvements were most pro-
nounced for the synthesis of ampicillin for all mutants, parti-
cularly with PGM that allowed up to four times higher product
accumulation than obtained with the wild-type enzyme. In
general, the six mutants showed similar trends in the test reac-
tions. Progress curves of triple mutant TM23 are shown as
examples in Figure 4.
In contrast to the correspondence in synthetic behavior,
the mutants were found to differ with respect to their amino
acid residue substitutions (Table I). Remarkably, TM33
showed only one amino acid residue change, bF24A, corre-
sponding to the bF24A E.coli PA single mutant that was
reported to allow high antibiotic yields (Alkema et al.,
2002a). However, improvements for the E.coli mutant
were most pronounced in the synthesis of cephalexin,
whereas TM33 performed best in the production of ampi-
cillin, in both cases using PGM as the acyl donor. Although
TM33 did not carry mutations at the other two sites, it was
confirmed as a true triple mutant by restriction analysis and
the presence of altered codons for residues aR160 and
aF161. The other five mutants contained amino acid sub-
stitutions at all three target positions. Although some muta-
tions, i.e. aR180K and aF181L, had earlier been found to
influence antibiotic synthesis in E.coli PA single mutants
Fig. 4. Synthesis of ampicillin and cephalexin by wild-type PAS2 and TM23, using 15 mM acyl donor and 25 mM b-lactam nucleophile. When the amide PGA was
used as the acyl donor, 75 nMwild-type and 7.5 mMmutant enzymewere used.With the ester PGM, 250 nMwild-type and 2.5 mMmutant enzymewere added. PAS2:
open circles, antibiotic; open squares, PG. TM23: closed circles, antibiotic; closed squares, PG.
Table I. Amino acid residue changes (bold) of improved mutants of
penicillin acylase PAS2
Name Mutations
TM23 aR160K aF161L bF24M
TM26 aR160Q aF161L bF24Q
TM33 aR160R aF161F bF24A
TM38 aR160P aF161A bF24V
TM42 aR160Q aF161R bF24I
TM48 aR160P aF161A bF24Q
E.M.Gabor and D.B.Janssen
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(Alkema et al., 2002a,b), the effects of most substitutions
and their combination have not been studied.
Kinetic characterization of the best mutants
Whereas antibiotic yields were clearly improved for all
mutants with PGA as the acyl donor (120–260%), synthesis
rates were strongly decreased, being <1% of the wild-type
rates. Activities with PGM were much higher for all mutants,
but mutants TM26, TM42 and TM48 still maximally reached
3.6% of the PAS2 synthesis rates. For a detailed kinetic char-
acterization, we therefore focused on the three other mutants,
TM23, TM33 and TM38, that exhibited 10–20% of the wild-
type activity in antibiotic formation. All experiments were
carried out with purified enzyme preparations.
The steady-state parameters for the hydrolysis of the acyl
donors used in this study and of the synthesized antibiotics are
summarized in Table II. In agreement with the low conversion
rates observed in the synthesis experiments, the kcat values of
all mutants for the acyl donors tested were decreased. TM23,
TM33 and TM38 showed a clear preference for hydrolysis of
the ester compared with the amide substrate. Surprisingly, the
wild-type enzyme was slightly more specific for the amide AD,
although enzyme-catalyzed ester hydrolysis is generally expec-
ted to be faster owing to the comparatively lower chemical
stability of the ester bond (Polgar, 1989). Although several
hypotheses exist that, for example, relate this unexpected
feature to a distortion of the normally planar amide
bond towards a structure that more resembles the tetrahedral
transition state that leads to the formation of the covalent
acyl-enzyme intermediate (James et al., 1980; Polgar, 1989;
Hedstrom et al., 1992), no structural evidence for the presence
of the proposed mechanisms in PA has yet been provided.
The increase in relative esterase/amidase activity of
the mutants was also reflected in their a parameters for the
synthesis of both ampicillin and cephalexin, which were much
lower with PGM as the acyl donor than with PGA (Table III).
Whereas with PGM the a values of all mutants were smaller
than that of the wild-type enzyme, partly explaining the high
antibiotic yields, a was up to 17-fold higher for the amide acyl
donor. This seems to be in contradiction with the observed
increase in antibiotic accumulation with PGA as the substrate.
However, not only the competition between antibiotic and
activated acyl donor for acylation of the enzyme determines
Psmax, but also the competition between the b-lactam nucleo-
phile N and water for deacylation of the covalent acyl-enzyme
intermediate (EAc), which is described by the parameters b0
and 1/g . With 10–40-fold increases in b0 and even up to
60 times higher values for 1/g (Table III), improvements
with respect to deacylation of EAc by the tested b-lactam
compounds were large enough to compensate for the relative
decrease of specificity for PGA compared with the antibiotic
Table III. Complex kinetic parameters a, b0 and g of penicillin acylase PAS2 and improved mutants
Enzyme Acyl donor Ampicillin Cephalexin
a b0 (mM1)a 1/gb a b0 (mM1)a 1/gb
PAS2 PGA 13.2 0.5 6 7.3 0.5 59
PGM 16.4 0.5 6 9.1 0.5 59
TM23 PGA 218 6.3 364 58.8 18.4 69
PGM 8.8 6.3 364 2.4 18.4 69
TM33 PGA 209 10.2 286 88.8 21.5 154
PGM 11.6 10.2 286 4.9 21.5 154
TM38 PGA 200 4.9 167 57.2 21.1 58
PGM 7.6 4.9 167 2.2 21.1 58
aMean of two independent experiments, using the amide PGA and the ester PGM as the acyl donor, respectively. Coefficient of variations were <12%.
bThe parameter g was obtained by fitting Ps vs Ph plots ([AD] = 15mM, [N] = 25mM)with Equation 1 and the experimentally determined values for the parametersa
and b0. The given value is the average obtained from analyzing two different curves, one with PGA and the other with PGM as the acyl donor. The coefficients of
variation were <10% for all data. Average values are given for b0 and 1/g , since these parameters are independent of the type of acyl donor used.
Table II. Steady-state kinetic parameters of penicillin acylase PAS2 and the improved mutants
Enzyme PGA PGM
kcat (s
1) Km (mM) kcat/Km (mM
1 s1) kcat (s
1) Km (mM) kcat/Km (mM
1 s1)
PAS2 25 12 2.1 24 14.3 1.7
TM23 0.7 122 0.006 2.0 13.4 0.15
TM33 0.13 29 0.0053 4.8 53.4 0.09
TM38 0.15 33 0.005 1.8 13.7 0.13
Ampicillin Cephalexin
kcat (s
1) Km (mM) kcat/Km (mM
1 s1) kcat (s
1) Km (mM) kcat/Km (mM
1 s1)
PAS2 16 0.6 26.7 20 1.3 15.4
TM23 3.4 2.6 1.31 0.6 1.7 0.35
TM33 2.3 2.2 1.05 0.4 0.9 0.44
TM38 2.4 2.4 1.00 0.8 2.8 0.29
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and allowed higher yields than with the wild-type enzyme.
Since the formation of both reaction products, Ps and Ph,
occurs via the same covalent intermediate (EAc), b0 and 1/g
should be independent of the type of AD used, which is in
agreement with our experimental results. Whereas for PAS2
(vPs/vPh)ini could be determined for a whole range of concen-
trations of the b-lactam nucleophile (1–200 mM), allowing the
experimental determination of both b0 and 1/g (Gabor et al.,
2004b), only b0 could be measured for the three mutants. This
is due to the fact that the synthetic reaction was so much
preferred with these enzymes that already at relatively low
nucleophile concentrations the amount of hydrolytic product
was below the detection limit in the initial phase of conversion.
Therefore, only b0 could be measured at 6-APA and 7-ADCA
concentrations below 5 mM, whereas 1/g needed to be obtained
by fitting [Ps] vs [Ph] plots that were derived from progress
curves (Figure 4) with Equation 1, using the experimental
values of a and b0. Good agreement was observed between
the data derived from curves based on the use of the amide
and the ester acyl donor (Figure 5), supporting the assumption
that the formation of the acyl-enzyme intermediate is the rate-
limiting step of the conversion.
Fig. 6. Maximumaccumulation of ampicillin and cephalexin in PA-catalyzed, kinetically controlled conversions, using different substrate concentrations. Data were
simulatedwithEquation 1, using the complex kinetic parametersa,b0 and g given inTable III. PAS2 (white); TM23 (black); TM33 (light gray); andTM38 (dark gray).
Fig. 5. Formation of synthesis product Ps (cephalexin) and hydrolytic
byproduct Ph (PG) during conversion of 7-ADCA and the amide acyl donor
PGA (open circles) or the ester PGM (closed circles) by TM38 penicillin
acylase. Lines represent fits obtained with Equation 1, using a = 57.2
(PGA), a = 2.2 (PGM) and b0 = 21.1 mM1. Values obtained for 1/g were
56 (PGA) and 59 (PGM).
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Interestingly, when 6-APA was used as the b-lactam nucleo-
phile, improvements were more pronounced for 1/g than for b0,
whereas with 7-ADCA the opposite situation occurred. For
mutants TM33 and 38, virtually no increase in 1/g was
observed in the synthesis of cephalexin. The high values of
(vPs/vPh)ini at low concentrations of 7-ADCA indicate that the
affinity for this b-lactam nucleophile became higher owing to
the mutations in the substrate binding pocket, while the exclu-
sion of water from the active site at high 7-ADCA concentra-
tions was obviously not improved. In contrast, binding of
6-APA in the active site seemed to suppress greatly the
nucleophilic attack of water on the acyl-enzyme intermediate.
Antibiotic yields at high substrate concentrations
In addition to by a, b0 and g , the maximum product yield of a
given reaction is also determined by the initial substrate con-
centrations [N]0 and [AD]0 and can, in homogeneous systems,
be calculated with Equation 1 as shown by Youshko and
Svedas (2000). To predict the performance of TM23, TM33
and TM38 at substrate concentrations higher than the experi-
mentally used levels, we modeled the maximum antibiotic
accumulation for a range of substrate concentrations in the
homogeneous regime, using the parameters given in Table III.
From Figure 6, it is apparent that all three mutants have
a higher potential for the synthesis of antibiotics derived
from 6-APA, particularly ampicillin, than from 7-ADCA.
Although higher yields of cephalexin are predicted for low
concentrations of 7-ADCA with PGA as the acyl donor,
which is in agreement with our experiments (Figure 4),
wild-type PAS2 allows significantly higher yields at nucleo-
phile concentrations above 50 mM with about 100-fold higher
conversion rates. When PGM and 6-APA are used, the draw-
back of lower activity (10–20% of wild-type) may, however,
become unimportant in view of the 4–5 times higher ampicillin
concentrations that can be reached over the whole range of
substrate concentrations. This is particularly interesting since
the reaction can be accelerated just by adding more enzyme,
while the maximum level of product accumulation that is
reached in a kinetically controlled synthesis reaction can
only be increased by using a better enzyme. The unproductive
loss of activated acyl donor is also drastically reduced when
using the mutant enzymes: at 200 mM 6-APA concentration,
about 80% of PGM is converted to ampicillin with the mutant
enzymes, whereas only 17% is used for synthesis with the wild-
type PAS2 penicillin acylase, the remainder being hydrolyzed
to D-phenylglycine (Figure 6).
In conclusion, our study demonstrates that focusing random
mutagenesis to amino acid residues that are expected to affect
the catalytic behavior of the target enzyme based on sequence
and structural information is an efficient tool for increasing the
frequency of biocatalysts with a desired property in a mutant
library. With this method, three mutant penicillin acylases
carrying different amino acid substitutions were recovered
that allow significantly higher ampicillin yields with PGM
than the wild-type enzyme, while retaining relatively high
catalytic activity.
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